Role of α-fetoprotein in hepatocellular carcinoma: Prognostication, treatment monitoring or both?

Future Oncology

Volumn 5, Issue 6, 2009, Pages 889-899

  Chan, Stephen L ^a   Chan, Anthonty T C ^a   Yeo, Winnie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

fetoprotein; Hepatocellular carcinoma; Monitoring treatment; Prognostic factor

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; TAMOXIFEN;

ADVANCED CANCER; ASCITES; BILIRUBIN BLOOD LEVEL; CANCER GRADING; CANCER INVASION; CANCER STAGING; DRUG RESPONSE; HUMAN; LIVER CELL CARCINOMA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; TUMOR VOLUME;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 70349222999     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.64     Document Type: Review

References (96)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827-841 (1999).
3. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogcnesis. Gastroenterology 132, 2557-2576 (2007).
4. Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48(Suppl. 1), S20-S37 (2008).
5. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003).
6. Johnson PJ: The role of serum α-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis. 5, 145-159 (2001).
7. Johnson PJ: Hepatocellular carcinoma: is current therapy really altering outcome? Gut 51, 459-462 (2002).
8. Leung TW, Patt YZ, Lau WY et al.: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res. 5, 1676-1681 (1999).
9. Barone RM, Byfield JE, Goldfarb PB, Frankel S, Ginn C, Greer S: Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases. Cancer 50, 850-862 (1982).
10. Lau WY, Leung TW, Lai BS et al.: Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann. Surg. 233, 236-241 (2001).
11. Johnson PJ: Critical issues in the design and implementation of clinical trials in hepatocellular carcinoma. Expert Rev. Anticancer Ther. 3, 421-423 (2003).
12. Bruix J, Sherman M, Llovet JM et al.: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421-430 (2001).
13. Hylton N: Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J. Clin. Oncol. 24, 3293-3298 (2006).
14. Lu JP, Wang J, Wang T, Wang Y, Wu WQ, Gao L: Microvessel density of malignant and benign hepatic lesions and MRI evaluation. World J. Gastroenterol. 10, 1730-1734 (2004).
15. Gharib AM, Thomasson D, Li KG: Molecular imaging of hepatocellular carcinoma. Gastroenterology 127, S153-S158 (2004).
16. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST: Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res. 63, 3121-3126 (2003).
17. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19, 1207-1225 (2001).
18. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS: Production of embryonal α-globulin by transplantable mouse hepatomas. Transplantation 1, 174-180 (1963).
19. Tatarinov YS: α-Fetoprotein in the laboratory testing for cancer. Gann 70, 133-139 (1979).
20. Stanislawski-Birencwajg M, Frayssinet C, Grabar P: Embryonic antigens in liver rumors in rats. Arch. Immunol. Ther. Exp. (Warsz.) 14, 730-736 (1966).
21. Javadpour N: The role of biologic tumor markers in testicular cancer. Cancer 45, 1755-1761 (1980).
22. McIntire KR, Waldmann TA, Moertel CG, Go VL: Serum α-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res. 35, 991-996 (1975).
23. Purves LR, Bersohn L Geddes EW: Serum α-feto-protein and primary cancer of the liver in man. Cancer 25, 1261-1270 (1970).
24. O'Conor GT, Tatarinov YS, Abelev GI, Uriel J: A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer 25, 1091-1098 (1970).
25. Daniele B, Bencivenga A, Megda AS, Tinessa V: α-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 127, S108-S112 (2004).
26. Wu JT: Serum α-fetoprotein and its lectin reactivity in liver diseases: a review. Ann. Clin. Lab. Sci. 20, 98-105 (1990).
27. Sell S, Becker FF, Leffert HL, Watabe L: Expression of an oncodevelopmental gene product (α-fetoprotein) during fetal development and adult oncogenesis. Cancer Res. 36, 4239-4249 (1976).
28. Li Y, Tang ZY, Ye SL et al.: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 7, 630-636 (2001).
29. Koide N, Nishio A, Igarashi J, Kajikawa S, Adachi W, Amano J: α-fetoprotein-producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis. Am. J. Gastroenterol. 94, 1658-1663 (1999).
30. Mizejewski GJ: Biological role of α-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev. Anticancer Ther. 2, 709-735 (2002).
31. Li MS, Li PF, He SP, Du GG, Li G: The promoting molecular mechanism of α fetoprotein on the growth of human hepatoma Bel7402 cell line. World. J. Gastroenterol. 8, 469-475 (2002).
32. Wang XW, Xie H: α-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci. 64, 17-23 (1999).
33. Li MS, Li PF, Yang FY, He SP, Du GG, Li G: The intracellular mechanism of α-fetoprotein promoting the proliferation of NIH 3T3 cells. Cell Res. 12, 151-156 (2002).
34. Dudich E, Semenkova L, Gorbatova E et al.: Growth-regulative activity of human α-fetoprotein for different types of tumor and normal cells. Tumour Biol. 19, 30-40 (1998).
35. Ikai I, Arii S, Kojiro M et al.: Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101, 796-802 (2004).
36. Ikeda K, Saitoh S, Koida I et al.: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18, 47-53 (1993).
37. Kumada T, Nakano S, Takeda I et al.: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25, 87-92 (1997).
38. Xu X, Ke QH, Shao ZX et al.: The value of serum α-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig. Dis. Sci. 54, 385-388 (2009).
39. Tateishi R, Shiina S, Yoshida H et al.: Prediction of recurrence of hepatocellular carcinoma after curative ablation using-three tumor markers. Hepatology 44, 1518-1527 (2006).
40. Guglielmi A, Ruzzenente A, Pachera S et al.: Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am. J. Gastroenterol. 103, 597-604 (2008).
41. Furihata T, Sawada T, Kita J et al.: Serum α-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology 55, 1705-1709 (2008).
42. Farinati F, Marino D, De Giorgio M et al.: Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am. J. Gastroenterol. 101, 524-532 (2006).
43. Ebara M, Ohto M, Shinagawa T et al.: Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22-patients. Gastroenterology 90, 289-298 (1986).
44. Zhou XD, Fang ZY, Yang BH et al.: Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 91, 1479-1486 (2001).
45. Vauthey JN, Lauwers GY, Esnaola NF et al.: Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 20, 1527-1536 (2002).
46. Poon RT, Fan ST, Lo CM, Liu CL, Wong J: Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann. Surg. 235, 373-382 (2002).
47. Taketa K, Sekiya C, Namiki M et al.: Lectin-reactive profiles of α-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 99, 508-518 (1990).
48. Sato Y, Nakata K, Kato Y et al.: Early recognition of hepatocellular carcinoma based on altered profiles of α-fetoprotein. N. Engl. J. Med. 328, 1802-1806 (1993).
49. Wang SS, Lu RH, Lee FY et al.: Utility of lentil lectin affinity of α-fetoprotein in the diagnosis of hepatocellular carcinoma. J. Hepatol. 25, 166-171 (1996).
50. Oka H, Saito A, Ito K et al.: Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive α-fetoprotein. J. Gastroenterol. Hepatol. 16, 1378-1383 (2001).
51. Sterling RK, Jeffers L, Gordon F et al.: Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am. J. Gastroenterol. 102, 2196-2205 (2007).
52. Leerapun A, Suravarapu SV, Bida JP et al.: The utility of Lens culinaris agglutinin-reactive α-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin. Gastroenterol. Hepatol. 5, 394-402; quiz 267 (2007).
53. Imamura J, Tateishi R, Shiina S et al.: Neoplastic seeding after radiofrequency ablation for hepatocellular-carcinoma. Am. J. Gastroenterol. 103, 3057-3062 (2008).
54. Yen YH, Changchien CS, Wang JH et al.: A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig. Liver Dis. 41(6); 431-441 (2009).
55. Sala M, Forner A, Varela M, Bruix J, Prognostic prediction in patients with hepatocellular carcinoma. Semin. Liver Dis. 25, 171-180 (2005).
56. Pons F, Varela M, Llovet JM: Staging systems in hepatocellular carcinoma. HPB (Oxford) 7, 35-41 (2005).
57. Abou-Alfa GK, Huitzil-Melendez FD, O'Reilly EM, Saltz LB: Current management of advanced hepatocellular carcinoma. Gastrointest. Cancer Res. 2, 64-70 (2008).
58. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28, 751-755 (1998).
59. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 31, 840-845 (2000).
60. Leung TW, Tang AM, Zee B et al.: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94, 1760-1769 (2002).
61. Lin CY, Kee KM, Wang JH et al.: Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 29, 74-81 (2009).
62. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J. Hepatol. 31, 133-141 (1999).
63. Tan CK, Law NM, Ng HS, Machin D: Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. J. Clin. Oncol. 21, 2294-2298 (2003).
64. McIntire KR, Vogel CL, Primack A, Waldmann TA, Kyalwazi SK: Effect of surgical and chemotherapeutic treatment on α-fetoprotein levels in patients with hepatocellular carcinoma. Cancer 37, 677-683 (1976).
65. McIntire KR, Vogel CL, Princler GL, Patel IR: Serum α-fetoprotein as a biochemical market for hepatocellular carcinoma. Cancer Res. 32, 1941-1946 (1972).
66. Johnson PJ, Williams R: Serum α-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J. Natl. Cancer Inst. 64, 1329-1332 (1980).
67. Lau WY, Ho S, Leung TW et al.: Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int. J. Radiat. Oncol. Biol. Phys. 40, 583-592 (1998).
68. Lo CM, Ngan H, Tso WK et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164-1171 (2002).
69. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL: A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94, 1747-1752 (2002).
70. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N. Engl. J. Med. 332, 1256-1261 (1995).
71. Chen LT, Liu TW, Chao Y et al.: α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment. Pharmacol. Ther. 22, 217-226 (2005).
72. Yeo W, Mok TS, Zee B et al.: A randomized Phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 97, 1532-1538 (2005).
73. Chan SL, Mo FK, Johnson PJ et al.: New utility of an old marker: serial α-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J. Clin. Oncol. 27, 446-452 (2009).
74. Cheng AL, Kang YK, Chen Z et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
75. Llovet JM, Ricci S, Mazzaferro V et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
76. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC: High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin mutations. Int. J. Cancer 112, 44-50 (2004).
77. Sugita S, Sasaki A, Iwaki K et al.: Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study. Eur. J. Surg. Oncol. 34, 339-345 (2008).
78. Hanazaki K, Kajikawa S, Koide N, Adachi W, Amano J: Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am. J. Gastroenterol. 96, 1243-1250 (2001).
79. Hiraoka A, Kumagi T, Hirooka M et al.: Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment. World J. Gastroenterol. 12, 2075-2079 (2006).
80. Ikeda M, Okada S, Yamamoto S et al.: Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Jpn. J. Clin. Oncol. 32, 455-460 (2002).
81. Llado L, Virgili J, Figueras J et al.: A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 88, 50-57 (2000).
82. Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP: Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or cirrhosis B: a multivariate analysis of prognostic factors. J. Clin. Gastroenterol. 28, 334-340 (1999).
83. O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST: Factors, predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br. J. Surg. 90, 325-331 (2003).
84. Doffoel M, Bonnetain F, Bouche O et al.: Multicentre randomised Phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402). Eur. J. Cancer 44, 528-538 (2008).
85. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J: Natural history of untreated nonsurgical hepatocellular carcinoma. Am. J. Gastroenterol. 100, 1995-2004 (2005).
86. Grieco A, Pompili M, Caminiti G et al.: Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54, 411-418 (2005).
87. Lerose R, Molinari R, Rocchi E, Manenti F, Villa E: Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur. J. Cancer 37, 239-245 (2001).
88. Hwang JP, Hassan MM: Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer 9, 46 (2009).
89. Nouso K, Ito YM, Kuwaki K et al.: Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br. J. Cancer 98(7), 1161-1165 (2008).
90. Changchien CS, Chen CL, Yen YH et al.: Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J. Gastroenterol. 43, 159-170 (2008).
91. Camma C, Di Marco V, Cabibbo G et al.: Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment, Pharmacol. Ther. 28, 62-75 (2008).
92. Yau T, Yao TJ, Chan P, Ng K, Fan ST, Poon RT: A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer 113, 2742-2751 (2008).
93. Tangkijvanich P, Anukulkarnkusol N, Suwangool P et al.: Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum α-fetoprotein levels. J. Clin. Gastroenterol. 31, 302-308 (2000).
94. Matsumoto Y, Suzuki T, Asada I, Ozawa K, Tobe T, Honjo I: Clinical classification of hepatoma in Japan according to serial changes in serum α-fetoprotein levels. Cancer 49, 354-360 (1982).
95. Sakata J, Shirai Y, Wakai T, Kaneko K, Nagahashi M, Hatakeyama K: Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur. J. Surg. Oncol. 34, 900-905 (2008).
96. Oishi K, Itamoto T, Amano H et al.: Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J. Surg. Oncol. 95, 311-316 (2007).